Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #74 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Dishman Carbogen Amcis Limited (this stock) | 2,375 | — | 1.5% | -47.4% | — | 35 | 100 | 11 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 678 | -51 | -58 | ₹ |
| March 31, 2026 | 851 | 46 | 22 | ₹ |
| Dec. 31, 2025 | 720 | -10 | -13 | ₹ |
| Sept. 30, 2025 | 653 | 31 | 65 | ₹ |
| June 30, 2025 | 708 | 39 | 23 | ₹ |
| March 31, 2025 | 716 | 28 | 43 | ₹ |
| Dec. 31, 2024 | 682 | 27 | 5 | ₹ |
| Sept. 30, 2024 | 789 | 42 | 33 | ₹ |
| June 30, 2024 | 524 | -78 | -78 | ₹ |
| March 31, 2024 | 655 | -49 | -70 | ₹ |
| Dec. 31, 2023 | 651 | -66 | -60 | ₹ |
| Sept. 30, 2023 | 587 | -36 | -41 | ₹ |
| June 30, 2023 | 723 | 29 | 17 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 2,932 | 105 | 97 |
| March 31, 2025 | 2,712 | 19 | 3 |
| March 31, 2024 | 2,616 | -122 | -153 |
| March 31, 2023 | 2,413 | -55 | -30 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 491 | -245 | 201 | 266 | 225 |
| March 31, 2025 | 375 | -192 | -102 | 217 | 158 |
| March 31, 2024 | 384 | -230 | -22 | 303 | 81 |
| March 31, 2023 | 220 | -448 | 250 | 574 | -354 |
| March 31, 2022 | 355 | -619 | 130 | 464 | -109 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 11,923 | 6,677 | 6,646 | 1,241 | 1,535 | 2,842 | 2,317 | 788 | 2,942 | 1,019 |
| March 31, 2025 | 9,999 | 5,832 | 5,800 | 935 | 1,149 | 2,200 | 1,925 | 341 | 2,684 | 900 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
